IPSEN S A/S (OTCMKTS:IPSEY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The brokerage currently has a $29.00 price target on the stock. Zacks Investment Research‘s target price indicates a potential upside of 7.01% from the company’s current price.
According to Zacks, “Ipsen S.A. is a pharmaceutical company. It provide drugs for urology, oncology, endocrinology, neurology, gastroenterology, cognitive disorders, rheumatology and cardiovascular. Ipsen S.A. is headquartered in Boulogne-Billancourt, France. “
Several other research analysts also recently commented on the stock. ValuEngine downgraded shares of IPSEN S A/S from a “hold” rating to a “sell” rating in a research note on Monday, August 3rd. JPMorgan Chase & Co. raised shares of IPSEN S A/S from a “neutral” rating to an “overweight” rating in a research note on Wednesday, July 22nd. Bank of America raised shares of IPSEN S A/S from a “neutral” rating to a “buy” rating in a research note on Monday, June 1st. Barclays reaffirmed an “equal weight” rating on shares of IPSEN S A/S in a research note on Friday, July 31st. Finally, Credit Suisse Group reaffirmed a “neutral” rating on shares of IPSEN S A/S in a research note on Monday, August 3rd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $29.00.
Shares of IPSEY opened at $27.10 on Tuesday. IPSEN S A/S has a twelve month low of $9.10 and a twelve month high of $28.62. The company has a market cap of $9.09 billion, a P/E ratio of 14.34 and a beta of 1.29. The company’s fifty day simple moving average is $25.30 and its 200-day simple moving average is $19.79.
About IPSEN S A/S
Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity.
Featured Story: How is a Moving Average Calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IPSEN S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN S A/S and related companies with MarketBeat.com's FREE daily email newsletter.